natgillin/translations-raw huggingface dataset:
Lesions that do not respond completely to treatment at 8 weeks after the second treatment cycle should be carefully re-evaluated and one additional 2-week treatment of Zyclara may be considered.
8. tednu po drugem ciklusu zdravljenja na zdravljenje ne odzovejo popolnoma, je treba skrbno ponovno ovrednotiti in razmisliti o enem dodatnem 2-tedenskem zdravljenju z zdravilom Zyclara
Methyl parahydroxybenzoate (E 218) 2.0 mg/g cream Propyl parahydroxybenzoate (E 216) 0.2 mg/g cream Cetyl alcohol 22.0 mg/g cream Stearyl alcohol 31.0 mg/g cream Benzyl alcohol 20.0 mg/g cream
metilparahidroksibenzoat (E218) 2,0 mg/g kreme propilparahidroksibenzoat (E216) 0,2 mg/g kreme cetilalkohol 22,0 mg/g kreme stearilalkohol 31,0 mg/g kreme benzil alkohol 20,0 mg/g kreme
If you forget to use Zyclara
Če ste pozabili uporabiti zdravilo Zyclara
Squamous cell carcinoma (SCC) was reported in 1.3% (2/160) of patients treated with imiquimod 3.75%, in 0.6% (1/159) treated with vehicle.
O karcinomu skvamoznih celic so poročali pri 1,3 % (2/160) bolnikov, zdravljenih z imikvimodom 3,75 %, ter pri 0,6 % (1/159)
Your doctor will discuss if you should discontinue breastfeeding or discontinue Zyclara treatment.
Zdravnik se bo z vami pogovoril, ali naj prenehate dojiti ali prekiniti zdravljenje z zdravilom Zyclara.
Local skin reactions can be a sign that the medicine is working as intended.
Lokalna reakcija je lahko znak, da zdravilo deluje.
After about 8 hours, wash the area where Zyclara was applied with mild soap and water.
Po 8 urah področje nanosa zdravila Zyclara umijte z blagim milom in vodo.
• Do not use sunlamps or tanning-beds, and avoid exposure to sunlight as much as possible during treatment with this medicine.
- Med zdravljenjem s tem zdravilom ne uporabljajte svetilk za sončenje ali solarijev ter se izogibajte sončni svetlobi, kolikor je le mogoče.
Actinic keratosis lesions that have cleared after two Zyclara treatment cycles of 2 weeks and subsequently recur can be re-treated with one or two further Zyclara treatment cycles of 2 weeks following an at least 12 weeks treatment pause.
Aktinične keratoze, ki so po dveh 2-tedenskih ciklih zdravljenja z zdravilom Zyclara izginile in se nato ponovno pojavile, je mogoče ponovno zdraviti s še enim ali dodatnima dvema 2-tedenskima cikloma zdravljenja z zdravilom Zyclara, po najmanj 12-tedenskem premoru brez zdravljenja.
The European Medicines Agency has waived the obligation to submit the results of studies with Zyclara in all subsets of the paediatric population in actinic keratosis (see section 4.2 for information on paediatric use).
Zyclara za vse podskupine pediatrične populacije pri aktinični keratozi (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Caution should be exercised when prescribing Zyclara to pregnant women.
Pri predpisovanju zdravila Zyclara nosečnicam je potrebna previdnost.
- Increase in liver enzymes There have been reports of increased liver enzymes.
Poročali so o povišanih vrednostih jetrnih encimov.
Furthermore, tumours were not seen at any site in a 2-year oral carcinogenicity study in rats.
Poleg tega se v dvoletni študiji kancerogenosti pri podganah pri peroralnem dajanju tumorji niso pojavili na nobenem mestu.
If you accidentally swallow this medicine please contact your doctor immediately.
Če ste pomotoma zaužili to zdravilo, nemudoma obvestite svojega zdravnika.
Boxes of 14, 28, and 56 single-use polyester/ white low density polyethylene/ aluminium foil sachets, containing 250 mg of cream.
Škatle po 14, 28 in 56 vrečic za enkratno uporabo iz poliesterske/bele z nizko gostoto polietilena/aluminijske folije, ki vsaka vsebuje 250 mg kreme.
Skin infection
Okužbe kože
Whilst using Zyclara and until healed, the treatment area is likely to appear noticeably different from normal skin.
Med zdravljenjem z zdravilom Zyclara in do dokončne ozdravitve bo zdravljeni predel najverjetneje izgledal opazno drugačno od običajne kože.
- Each box contains 14, 28 or 56 single-use polyester/ white low density polyethylene/aluminium foil sachets.
- Ena škatla vsebuje 14, 28 ali 56 vrečic za enkratno uporabo iz poliesterskega/belega polietilena z nizko gostoto/aluminijske folije.
Zyclara is for external use only.
Način uporabe Zdravilo Zyclara je primerno samo za zunanjo uporabo.
Up to 2 sachets of Zyclara may be applied to the treatment area (full face or scalp, but not both) at each daily application.
Na zdravljeni predel se lahko vsak dan naneseta do 2 vrečici zdravila Zyclara (celoten obraz ali lasišče, vendar ne oboje).
An interruption of dosing or dose adjustment should be considered (see section 4.8).
V takih primerih je treba razmisliti o prilagoditvi odmerka (glejte poglavje 4.8).
Local skin reactions are common but these reactions generally decrease in intensity during therapy or resolve after cessation of imiquimod cream therapy.
Lokalne kožne reakcije so pogoste, vendar se njihova intenzivnost med zdravljenjem navadno zmanjša oziroma po prekinitvi zdravljenja z imikvimod kremo izzvenijo.
It is unknown whether imiquimod/metabolites are excreted in human milk.
Ni znano, ali se imikvimod/presnovki izločajo v materino mleko.
If you stop using Zyclara
Če ste prenehali uporabljati zdravilo Zyclara
Use in immunocompromised patients and/or in patients with autoimmune conditions The safety and efficacy of Zyclara in immunocompromised patients (e.g. organ transplant patients) and/or patients with autoimmune conditions have not been established.
Varnost in učinkovitost zdravila Zyclara pri bolnikih z oslabljenim imunskim sistemom (npr. bolnikih s presajenimi organi) in/ali bolnikih z avtoimunskimi boleznimi nista bili ugotovljeni.
For the combined trials the complete clearance rate of the full face or balding scalp under imiquimod 3.75% cream was 35.6% (57/160 patients, CI 28.2%, 43.6 %) under vehicle 6.3% (10/159 patients, CI 3.1%, 11.3%) at the 8-week post-treatment visit.
V vseh preskušanjih je bila stopnja celotnega očistka 8 tednov po končanem zdravljenju po uporabi imikvomod 3,75 % kreme na področju celotnega obraza ali neporaščenega lasišča 35,6 % (57/160 bolnikov, interval zaupanja (IZ) 28,2 %, 43,6 %), po uporabi vehikla pa 6,3 % (10/159 bolnikov, IZ 3,1 %, 11,3 %).
If you have applied too much cream, wash the extra away with mild soap and water.
Če ste nanesli preveč kreme, sperite odvečno kremo z blagim milom in vodo.
Serious skin reactions (frequency not known) with skin lesions or spots on your skin that start out as small red areas and progress to look like mini targets, possibly with symptoms such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy eyes and mouth sores.
Hude kožne reakcije (neznana pogostnost) z lezijami ali drobne pike, ki se razvijejo v majhne rdeče lise, ki se lahko še naprej povečujejo in ki jih lahko spremljajo simptomi kot so srbenje, vročina, splošno slabo počutje, boleči sklepi, težave z vidom, pekoč občutek, boleče ali srbeče oči in razjede v ustih.
- The active substance is imiquimod.
- Učinkovina je imikvimod.
What Zyclara looks like and contents of the pack
Izgled zdravila Zyclara in vsebina pakiranja
- experience with imiquimod 5% cream
- izkušnje z uporabo imikvimod 5 % kreme.
In addition, release of cytokines was induced following dermal application and oral administration of imiquimod in various laboratory animals and in human studies.
Sproščanje citokinov je bilo inducirano po dermalni in peroralni uporabi imikvimoda tudi pri različnih drugih laboratorijskih živalih in v študijah na ljudeh.
Each sachet contains 9.375 mg of imiquimod in 250 mg cream (100 mg of cream contains 3.75 mg imiquimod).
Ena vrečica vsebuje 9,375 mg imikvimoda v 250 mg kreme (100 mg kreme vsebuje 3,75 mg imikvimoda).
Zyclara has no or negligible influence on the ability to drive and use machines.
Zdravilo Zyclara nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Cream.
krema
While using Zyclara, you may experience local skin reactions because of the way it acts on your skin.
Med zdravljenjem z zdravilom Zyclara boste morda občutili lokalne kožne reakcije, ki izvirajo iz njenega lokalnega delovanja na kožo.
The treatment area is the full face or balding scalp.
Predela zdravljenja sta celoten obraz ali neporaščeno lasišče.
Rare (may affect up to 1 in 1,000 people) - Flaring up of autoimmune conditions (a disease that results from an abnormal immune response is an autoimmune disease) - Skin reactions remote from the application site
Redki (pojavijo se pri 1od 1.000 bolnikov) - poslabšanje avtoimunskih obolenj (bolezen, ki je posledica nenormalnega imunskega odziva,
- Each Zyclara 3.75% cream sachet contains 250 mg of a white to slightly yellow cream with a uniform appearance.
- Ena vrečica zdravila Zyclara 3,75 % krema vsebuje 250 mg bele do svetlo rumene kreme z enotnim videzom.
Each sachet contains 9.375 mg of imiquimod in 250 mg cream (3.75%).
Ena vrečica vsebuje 9,375 mg imikvimoda v 250 mg kreme (3,75 %).
In case a dose is missed, patients should wait until the forthcoming night to apply Zyclara and then continue with the regular schedule.
Če bolnik pozabi uporabiti odmerek, naj počaka do naslednjega večera in zdravilo Zyclara uporabi takrat, nato pa naj nadaljuje z običajnim urnikom zdravljenja.
Zyclara 3.75% cream contains the active substance imiquimod, which is an Immune Response Modifier (to stimulate the human immune system).
Zdravilo Zyclara 3,75 % krema vsebuje učinkovino imikvimod, ki je modifikator imunskega odziva
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development (see section 5.3).
Študije na živalih ne kažejo neposrednih ali posrednih škodljivih učinkov na nosečnost, razvoj zarodka/plodu,
Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, mutagenicity and teratogenicity.
Neklinični podatki na osnovi običajnih študij farmakološke varnosti, mutagenosti in teratogenosti ne kažejo posebnega tveganja za človeka.
In these studies, the treated AK field was located on the balding scalp or face with a contiguous area of about 40 cm² and presenting with a median number of 7 clinically typical AK lesions at baseline.
V teh študijah so se zdravljeni AK predeli nahajali na neporaščenem lasišču ali obrazu s sklenjeno površino približno 40 cm², mediana števila klinično značilnih AK lezij v izhodišču je bila 7.
If flu-like symptoms or feeling discomfort or intense local skin reactions occur, a rest period of several days may be taken.
Če se pojavijo gripi podobni simptomi, občutek neugodja ali hude kožne reakcije, lahko vzamete nekaj dni premora.
The incidence corresponds well with the spectrum of spontaneous tumours, as is known in mice in correspondence with their age.
Pojavnost se ujema z znano stopnjo pojavnosti spontanih tumorjev pri miših, v odvisnosti od starosti živali.
You should continue application for the full treatment course even if all actinic keratosis appear to be gone.
Z nanašanjem kreme morate nadaljevati skozi celoten ciklus zdravljenja, tudi če se zdi, da so vse aktinične keratoze izginile.
Cetyl alcohol and stearyl alcohol may cause local skin reactions (e.g. contact dermatitis).
Cetilalkohol in stearilalkohol lahko povzročita lokalne kožne reakcije (npr. kontaktni dermatitis).
Zyclara should be applied as a thin film to the entire treatment area and rubbed in until the cream vanishes.
Zdravilo Zyclara je treba v zelo tankem sloju nanesti na celotno zdravljeno področje in ga vtreti v kožo, dokler se ne vpije.
How to use Zyclara
Kako uporabljati zdravilo Zyclara
Content of the pack and other information
Shranjevanje zdravila Zyclara Vsebina pakiranja in dodatne informacije
Patients with cardiac, hepatic or renal impairment were not included in clinical trials.
Bolniki z okvaro srca, jeter ali ledvic v klinične študije niso bili vključeni.
Dry hands thoroughly and allow the area to dry.
Roke in zdravljeni predel nato skrbno osušite.
General instructions during treatment
Splošna navodila, ki jih je treba upoštevati med zdravljenjem
Imiquimod is not recommended for the treatment of AK lesions with marked hyperkeratosis or hypertrophy as seen in cutaneous horns.
Uporaba imikvimoda ni priporočena za zdravljenje AK lezij z izrazito hiperkeratozo ali hipertrofijo,
When applied topically, systemic overdose with imiquimod cream is unlikely due to minimal percutaneous absorption.
Sistemsko preveliko odmerjanje imikvimod kreme po lokalnem nanašanju ni verjetno zaradi minimalne perkutane absorpcije.
Apply a thin layer of Zyclara to the affected area.
Nanesite tanek sloj zdravila Zyclara na zdravljeni predel.
Treatment with imiquimod cream can be resumed after the skin reaction has moderated.
Zdravljenje z imikvimod kremo lahko nadaljujete, ko se kožne reakcije umirijo.
Stearyl alcohol and cetyl alcohol may cause local skin reactions (e.g. contact dermatitis).
Stearilalkohol in cetilalkohol lahko povzročita lokalne kožne reakcije (npr. kontaktni dermatitis).
In a follow-up study where initially cleared patients with imiquimod 3.75% were followed for at least 14 months without any further AK-treatment, 40.5% of the patients showed sustained complete clearance of the whole treatment area (either full face or scalp) There are no data for imiquimod 3.75% on long-term clearance beyond that.
V nadaljevalni študiji, v kateri so najmanj 14 mesecev opazovali bolnike, ki so se zdravili z imikvomod 3,75 % in pri katerih so lezije na začetku izginile, nato pa niso več prejemali kakršnega koli nadaljnjega zdravljenja AK, se je pri 40,5 % bolnikov pokazala trajna popolna odprava na celotnem zdravljenem področju (bodisi celotnem obrazu ali lasišču).
Because of concern for heightened sunburn susceptibility, use of sunscreen is encouraged, and patients should minimise or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using Zyclara.
bolniki pa naj med zdravljenjem z zdravilom Zyclara omejijo izpostavljanje naravni ali sončni svetlobi (uporaba solarija ali zdravljenje z UVA/B svetilkami) oziroma se mu izogibajo.
Remote site dermatologic reactions
Dermatološke reakcije na oddaljenih mestih
Avoid contact with the eyes, lips and nostrils.
- Preprečite stik z očmi, ustnicami in nosnicami.
Do not cover the treated area with bandages or other dressings.
Zdravljenega predela ne prekrivajte s povoji ali obvezami.
If you miss a dose of Zyclara, wait until the next night to apply it and then continue with the regular schedule.
Če ste pozabili nanesti zdravilo Zyclara, počakajte in kremo nanesite naslednji večer, nato nadaljujte z običajnim urnikom zdravljenja.
Flu-like systemic signs and symptoms may accompany, or even precede, intense local skin reactions and may include fatigue, nausea, fever, myalgias, arthralgias, and chills.
Gripi podobni znaki in simptomi lahko spremljajo burne lokalne kožne reakcije, ki lahko zajemajo utrujenost, navzeo, zvišano telesno temperaturo, mialgije, artralgije in mrazenje, ali se celo pojavijo pred njimi.
Animals were administered imiquimod cream three times per week and were irradiated 5 days per week for 40 weeks.
Živalim so dajali imikvimod trikrat tedensko,
If your skin reacts badly or becomes too uncomfortable when using this medicine, stop applying the cream and wash the area with mild soap and water.
Če vaša koža resno reagira na to zdravilo ali povzroči čezmerno nelagodje, prenehajte z uporabo, umijte področje nanosa z blagim milom in vodo ter čim prej obvestite zdravnika ali farmacevta.
Methyl parahydroxybenzoate (E 218), and propyl parahydroxybenzoate (E 216), may cause allergic reactions (possibly delayed).
Metilparahidroksibenzoat (E 218) in propilparahidroksibenzoat (E2 16) lahko povzročita alergijske reakcije (lahko zapoznele).
A rest period of several days may be taken if required by the patient's discomfort or severity of the local skin reaction.
Če je potrebno, se lahko zdravljenje zaradi nelagodja bolnika ali resnosti lokalne reakcije na koži za nekaj dni prekine.
Methyl parahydroxybenzoate (E 218), and propyl parahydroxybenzoate (E 216) may cause allergic reactions (possibly delayed).
Metilparahidroksibenzoat (E218) in propilparahidroksibenzoat (E216) lahko povzročita alergijske reakcije (lahko zapoznele).
Saturable binding studies suggest membrane receptors for imiquimod exists on responding cells; these are called toll-like receptor 7 and 8.
imenujejo se tollu-podoben receptor 7 in 8.
Open a new sachet of Zyclara just before use and squeeze some cream onto your fingertip.
Zyclara in iztisnite nekaj kreme na konico prsta.
Zyclara (per application: up to 2 sachets, 250 mg imiquimod cream per sachet) should be applied once daily before bedtime to the skin of the affected treatment field (area) for two treatment cycles of 2 weeks each separated by a 2-week no-treatment cycle or as directed by the physician.
Zdravilo Zyclara (za en nanos: do 2 vrečici, 250 mg imikvimod kreme na vrečico) nanašamo enkrat na dan pred spanjem na kožo prizadetega predela v dveh dva tedna trajajočih ciklusih zdravljenja, med katerima je dvotedensko obdobje premora brez zdravljenja, če zdravnik ne odredi drugače.
If you experience these, stop using this medicine and tell your doctor immediately.
Če se pri vas pojavi kaj od naštetega, prenehajte uporabljati to zdravilo in se čim prej posvetujte z zdravnikom.
You should not use Zyclara if you are breast-feeding or plan to breast-feed.
Zdravila Zyclara ne smete uporabljati, če dojite ali nameravate dojiti.
Patients with reduced haematologic reserve have not been studied in clinical trials.
Bolnikov z zmanjšanimi hematološkimi vrednostmi v kliničnih preskušanjih niso preučevali.
Rub gently into the area until the cream vanishes.
Kremo nežno vtirajte v kožo, dokler se popolnoma ne vpije.
This might make you more susceptible to infections, make you bruise more easily or cause tiredness.
Zaradi zmanjšanega števila krvnih celic ste lahko bolj dovzetni za okužbe in pojav modric ali ste bolj utrujeni.
- Throat pain - Eye irritation - Swelling of the eyelid - Depression - Irritability - Dry mouth - Abdominal pain
- depresija, - razdražljivost, - suha usta,
During a pharmacokinetic study with imiquimod 3.75% cream following application of 2 sachets once daily (18.75 mg imiquimod/day) for up to three weeks to the entire face and/or scalp (approximately 200 cm2), low systemic absorption of imiquimod was observed in patients with AK. Steady-state levels were achieved in 2 weeks and time to maximal concentrations (Tmax) ranged between 6 and 9 hours after last application.
Med farmakokinetično študijo z imikvimod 3,75 % kremo so pri bolnikih z AK, ki so do tri tedne na celotni obraz in/ali lasišče (približno 200 cm2) nanašali 2 vrečici (18,75 mg imikvimoda/dan) na dan, opazili nizko sistemsko absorpcijo imikvimoda.
You should continue treatment as prescribed.
Nadaljujte z zdravljenem, kot vam je predpisal zdravnik.
319 subjects with AK were treated with up to 2 sachets once daily of imiquimod 3.75% cream, or a matching vehicle cream for two treatment cycles of 2 weeks separated by a 2-week no-treatment cycle.
319 preiskovancev z AK je bilo zdravljenih z do 2 vrečicama imikvimod 3,75 % kreme na dan ali ujemajočo se kremo z vehiklom v dveh 2-tedenskih ciklusih zdravljenja, med katerima je bil 2-tedenski odmor brez zdravljenja.
Zyclara contains methyl parahydroxybenzoate, propyl parahydroxybenzoate, cetyl alcohol, stearyl alcohol and benzyl alcohol
Zdravilo Zyclara vsebuje metilparahidroksibenzoat, propilparahidroksibenzoat, cetilalkohol, stearilalkohol in benzil alkohol
However, neither 2-week treatment cycle should be extended due to missed doses or rest periods.
V nobenem primeru pa se posameznega dvotedenskega ciklusa zdravljenja ne sme prekoračiti zaradi pozabljenih odmerkov ali obdobij prekinitve.
Subjects applied up to two sachets of Zyclara 3.75% cream or vehicle daily to the skin of the affected area (either entire face or balding scalp, but not both) for two 2-week treatment cycles separated by a 2-week no-treatment cycle.
Zyclara 3,75 % krema ali vehikla na površino prizadetega predela (bodisi celoten obraz bodisi neporaščeno lasišče, vendar ne oboje) v dveh 2-tedenskih ciklusih zdravljenja, med katerima je bilo 2tedensko obdobje premora brez zdravljenja.
United Kingdom.
Združeno kraljestvo (Velika Britanija).
- The other ingredients are isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, white soft paraffin, polysorbate 60, sorbitan stearate, glycerol, methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), xanthan gum, purified water (see also section 2 “Zyclara contains methyl parahydroxybenzoate, propyl parahydroxybenzoate, cetyl alcohol, stearyl alcohol and benzyl alcohol”).
- Druge sestavine zdravila so izostearinska kislina, benzilalkohol, cetilalkohol, stearilalkohol, beli vazelin, polisorbat 60, sorbitan stearat, glicerol, metilparahidroksibenzoat (E 218), propilparahidroksibenzoat (E 216), ksantanski gumi, prečiščena voda (glejte tudi poglavje 2 ‘'Zdravilo Zyclara vsebuje metilparahidroksibenzoat, propilparahidroksibenzoat, cetilalkohol, stearilalkohol in benzil alkohol'').
Imiquimod is an immune response modifier.
Farmakodinamični učinki Imikvimod je modulator imunskega odziva.
Application to broken skin could result in increased systemic absorption of imiquimod leading to a greater risk of adverse events (see section 4.8 and 4.9).
Nanašanje kreme na poškodovano kožo lahko privede do zvečanja sistemske absorpcije imikvimoda, kar lahko poveča tveganje za pojav neželenih učinkov (glejte poglavji 4.8 in Zaradi tveganja za večjo dovzetnost za sončne opekline se priporoča uporaba zaščitne sončne kreme,
Rare (≥ 1/10,000 to < 1/1,000);
zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/1.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov)
Patients with hepatic or renal impairment were not included in clinical trials.
Bolniki z okvaro jeter ali ledvic niso bili vključeni v klinične študije.
Topical in vivo application of imiquimod cream on mouse skin resulted in increased concentrations of IFN and tumour necrosis factor (TNF) compared with skin of untreated mice.
V in vivo pogojih je lokalno nanašanje imikvimod kreme na kožo miši, v primerjavi s kožo nezdravljenih miši, povzročilo zvišanje koncentracij IFN in tumorje nekrotizirajočega faktorja
Very rare (<1/10,000) and not known (cannot be estimated from the available data)
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)
Excipients: isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, white soft paraffin, polysorbate 60, sorbitan stearate, glycerol, methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), xanthan gum, purified water.
Pomožne snovi: izostearinska kislina, benzilalkohol, cetilalkohol, stearilalkohol, beli vazelin, polisorbat 60, sorbitan stearat, glicerol, metilparahidroksibenzoat (E218), propilparahidroksibenzoat (E216), ksantanski gumi, prečiščena voda.
Talk to your doctor or pharmacist before using Zyclara:
Pred začetkom uporabe zdravila Zyclara se posvetujte z zdravnikom ali farmacevtom:
Patients had 5-20 typical visible or palpable AK lesions in an area that exceeded 25 cm2 on either the face or balding scalp.
Bolniki so imeli 5-20 klinično značilnih, vidnih ali otipljivih AK
Loughborough Leicester
Loughborough
Systemic exposure (percutaneous penetration) was calculated from recovery of carbon-14 from [14C] imiquimod in urine and faeces.
14 [14C] iz imikvimoda v urinu in blatu.
This medicine may also cause flu-like symptoms (including tiredness, nausea, fever, muscle and joint pain, and shivering) before or during the occurrence of local skin reactions.
To zdravilo lahko pred pojavom lokalnih kožnih reakcij ali med njim povzroči tudi gripi podobne simptome (vključno z utrujenostjo, siljenjem na bruhanje, zvišano telesno temperaturo, bolečinami v mišicah in sklepih ter mrazenjem).